• HER connection
  • Her connection

    Discover a program designed to support patients with knowledge and information about HER2+ breast cancer.

    Three ways to connect:

  • Receive Updates
    Personalized information to support your treatment

  • Support Line
    Call 866.449.HER2 Nurses available 24/7

  • Online Live Chat
    Nurses available Monday-Friday, 8am EST to 8pm EST.

Coverage and Reimbursement

Herceptin Access Solutions

Herceptin Access Solutions

Herceptin Access Solutions™ – connecting you to the medicine you need. If you are worried about paying for one our medicines, we can help.

Regardless of your insurance status, we can help:

  • Find out if your health plan pays for your medicine
  • Guide you through the reimbursement process
  • Connect you with programs to help you with out-of-pockets costs
  • Give you and your doctor's office personal help from a member of our support team

If you have no insurance, we can help you get your medicine free of charge.

To learn more about how we can help you or a loved one, call (888) 249-4918 to speak live with one of our specialists or visit HerceptinAccessSolutions.com

When seeking coverage and reimbursement from Herceptin Access Solutions, there are two forms you and your doctor will need to complete:

  • Statement of Medical Necessity (SMN) form – a form filled out by your doctor.
  • Patient Authorization and Notice of Release of Information (PAN) form – a form you must sign and date. This form gives Genentech written permission to discuss your case with you, your health care provider and your health insurance company.

When you or your doctor's office calls Herceptin Access Solutions, we will connect you with one of our dedicated Specialists whose only job is to work with you to get the help you need to cover the cost of your medicine.

Herceptin Access Solutions Specialists look at what you may need to know about your health insurance plan's coverage and issues that may affect reimbursement for use of our medicines.

You may have a private health insurance plan or be covered by Medicare or Medicaid. We can help you with issues that include:

  • What your health insurance plan really covers (known as “benefits investigation”)
  • Whether your insurer must approve use of a specific Genentech medicine before your treatment begins (known as “prior authorization”)
  • What happens if the insurer decides you are not covered for a specific Genentech medicine (known as “denial,” which can be appealed)

To speak live with one of our Specialists, call (888) 249-4918 from 6 a.m. – 5 p.m. PT, Monday to Friday, fax (888) 249-4919 or visit HerceptinAccessSolutions.com

Genentech Access to Care Foundation (GATCF)

The Genentech Access to Care Foundation (GATCF) helps patients who do not have insurance coverage for a Genentech medicine. Qualified patients enrolled in GATCF receive their medicine free of charge.

  • We are committed to helping you get our medicines regardless of your ability to pay
  • If you have no insurance, or your health insurance plan denies you coverage for Herceptin, you can work with your doctor's office to apply to GATCF for free medicine

To speak live with one of our Specialists, call (800) 520-3083 from 6 a.m. – 5 p.m. PT, Monday to Friday, fax (877) 428-2326 or visit HerceptinAccessSolutions.com

Who is Herceptin for?

Herceptin is approved for the adjuvant treatment of HER2-overexpressing, node-positive or node-negative (ER/PR-negative or with one high-risk feature)† breast cancer. Herceptin can be used several different ways:

  • As part of a treatment regimen including doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy

Herceptin in combination with paclitaxel is approved for the first-line treatment of HER2-overexpressing metastatic breast cancer. Herceptin as a single agent is approved for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.

† High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.

What important safety information should I know about Herceptin?

Herceptin treatment can result in heart problems, including those without symptoms (reduced heart function) and those with symptoms (congestive heart failure). The risk and seriousness of these heart problems were highest in people who received both Herceptin and a certain type of chemotherapy (anthracycline). Your doctor will stop or strongly consider stopping Herceptin if you have a significant drop in your heart function.

You should be monitored for decreased heart function before your first dose of Herceptin, and frequently during the time you are receiving Herceptin and after your last dose of Herceptin. If you must permanently or temporarily stop Herceptin due to heart problems, you should be monitored more frequently. In one study with Herceptin and certain types of chemotherapy, an inadequate blood supply to the heart occurred.

Some patients have had serious infusion reactions and lung problems; fatal infusion reactions have been reported. In most cases, these reactions occurred during or within 24 hours of receiving Herceptin. Your Herceptin infusion should be temporarily stopped if you have shortness of breath or very low blood pressure. Your doctor will monitor you until these symptoms go away. If you have a severe allergic reaction, swelling, lung problems, inflammation of the lung, or severe shortness of breath, your doctor may need to completely stop your Herceptin treatment.

Worsening of low white blood cell counts associated with chemotherapy has also occurred.

Herceptin can cause low amniotic fluid levels and harm to the fetus when taken by a pregnant woman.

The most common side effects associated with Herceptin were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, shortness of breath, rash, low white and red blood cells, and muscle pain.

Because everyone is different, it is not possible to predict what side effects any one person will have. If you have questions or concerns about side effects, talk to your doctor.

Please see the Herceptin full Prescribing Information including Boxed WARNINGS and additional important safety information.



Herceptin® (trastuzumab)Herceptin® (trastuzumab)

Adjuvant Care Is defined as additional treatment given after the main treatment plan to decrease the chance of recurrence. Adjuvant therapy for breast cancer can include chemotherapy, hormone therapy, radiation therapy, or biological therapy

Metastatic Breast Cancer Breast cancer that has spread to other sites in the body; also referred to as invasive or infiltrating